Interferon beta1a and depression in secondary progressive MS: data from the SPECTRIMS Trial.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 12221168.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Depression is a suspected side effect of treatment with interferon beta1a in MS. However, an association with depression has not been confirmed by rigorous studies. During the SPECTRIMS clinical trial of interferon beta1a (Rebif) in secondary progressive MS, depression ratings were obtained from 365 subjects treated either with interferon beta1a or with placebo. No significant differences between groups emerged during 36 months of follow-up. These data suggest that depression is not a side effect of interferon beta1a.
Medical subject headings
- Adjuvants, Immunologic
- Depression
- Interferon-beta
- Multiple Sclerosis, Chronic Progressive